Streamlining Drug Developments Through the In Silico Approach to Ligand-Target Interactions

A dramatic and controversial scenario that starts ab ovo i.e., from a bench to clinical trial-once the developments of a new drug is the case takes a lot of time and resources, while the In Silico research paradigm might make this track shorter with no quality losses beyond. As seen from computational models showing their efficiency in applied epigenomics, chemical physics and experimental pharmacology studies, the In Silico prediction of some key patterns of a preclinical trial landscape, based on both biochemical and mathematical logic, seems to be realistic and, therefore, legitimate task. This itself means a necessity of the careful analysis over the broad variety of data as long as they deal with a problem of computational tool applicable to the preclinical trial optimization efforts. This what a present work is all about.